Holen Sie sich die Stockscreener-App
89.35
1.61%
1.42
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$87.93
Offen:
$87.825
24-Stunden-Volumen:
14.52M
Relative Volume:
3.09
Marktkapitalisierung:
$33.72B
Einnahmen:
$4.82B
Nettoeinkommen (Verlust:
$930.40M
KGV:
38.21
EPS:
2.3381
Netto-Cashflow:
$1.43B
1W Leistung:
+7.61%
1M Leistung:
-0.28%
6M Leistung:
+32.06%
1J Leistung:
+17.91%
1-Tages-Spanne:
$87.39
$89.92
1-Wochen-Bereich:
$83.25
$89.92
52-Wochen-Spanne:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
89.35 | 31.33B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
102.61 | 176.41B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.13 | 116.35B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.12 | 105.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.34 | 62.29B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.26 | 48.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DexCom Inc Share PriceDXCM, RNS News, Articles, Quotes, & Charts (NASDAQ:DXCM) - Proactive financial news
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom (DXCM) Expands Board to 13 Directors with Appointment of Glenn S. Boehnlein - GuruFocus
Dexcom stock heads into the open after a 0.8% Nasdaq pullback - ad-hoc-news.de
Dexcom Appoints Glenn Boehnlein to Board of Directors - BioSpace
DexCom Expands Board with Glenn Boehnlein Appointment and Details Compensation Plan - Kalkine Media
DexCom, Inc. Announces Appointment of Glenn S. Boehnlein as Director, Member of Operations & Innovation Committee and Audit Committee, Effective September 10, 2026 - marketscreener.com
Dexcom (NASDAQ: DXCM) director gets 5,841-unit stock grant vesting over 3 years - Stock Titan
Dexcom (DXCM) director discloses 42-share trust stake - Stock Titan
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance UK
DexCom appoints Glenn S. Boehnlein to Board and committees - TradingView
Dexcom (NASDAQ: DXCM) officer lines up six‑figure stock sale - Stock Titan
How Dexcom Inc. (DXCM) Affects Rotational Strategy Timing - Stock Traders Daily
Dexcom Inc. stock steadies near mid-range as conference outlines growth plan - ad-hoc-news.de
DexCom expects CONNECT study on type 2 diabetes to be published soon in a major journal. - Pluang
Dexcom at Wells Fargo conference: coverage push drives growth plan By Investing.com - Investing.com India
Transcript : DexCom, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08:00 AM - marketscreener.com
DexCom Stock: Is DXCM Underperforming the Healthcare Sector? - webull.com
Dexcom stock heads into the open after a 3.8 percent drop - ad-hoc-news.de
Kakao Healthcare Lends Glucose Monitors to Diabetic Exam Takers - Seoul Economic Daily
DexCom Inc (DXCM) Shares Fall 3.8% -- What GF Score of 95 Tells Investors - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Law firm probes DexCom officers for possible br... - Pluang
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
DexCom, Inc. (DXCM) Stock Analysis: A Strong Buy With 7% Upside Potential - DirectorsTalk Interviews
Dexcom Inc. stock holds near consensus target on solid Q2 2026 growth - ad-hoc-news.de
Dexcom stock holds near USD 89.71 after strong Q2 - AD HOC NEWS
DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair - Yahoo Finance
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - finance.yahoo.com
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services - Barron's
ETFs Investing in DexCom, Inc. Stocks - TradingView
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Eastern Progress
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
3 Reasons DXCM Has Explosive Upside Potential - finance.yahoo.com
Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today - qz.com
Dexcom Announces Upcoming Conference Presentation - Business Wire
G7 Momentum and Global Reach Might Change The Case For Investing In DexCom (DXCM) - simplywall.st
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings And A Promising 3.63% Upside - DirectorsTalk Interviews
Dexcom (DXCM) HR chief cashes out 2,565 company shares - stocktitan.net
Dexcom Defeats Investor Suit Over Glucose Monitor Market Share - Bloomberg Law News
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking - Sahm
DexCom (NASDAQ: DXCM) officer may sell 2,565 shares on Aug. 27, 2026 - Stock Titan
We Ran A Stock Scan For Earnings Growth And DexCom (NASDAQ:DXCM) Passed With Ease - Moomoo
Dexcom (NASDAQ: DXCM) officer keeps 101,502 shares after tax withholding - Stock Titan
Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now? - Eastern Progress
Dexcom (NASDAQ: DXCM) CEO retains 418,908 shares after tax withholding - Stock Titan
Dexcom (NASDAQ: DXCM) chair sells 26,756 shares around $90 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
DexCom (NASDAQ:DXCM) Reaches New 52-Week HighStill a Buy? - MarketBeat
DexCom stock hits 52-week high at 91.99 USD - Investing.com
DexCom Study Demonstrates CGM Benefits in Type 2 Diabetes - Medical Product Outsourcing
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dexcom Inc-Aktie (DXCM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Sale |
84.02 |
1,550 |
130,231 |
35,832 |
| Brown Michael Jon | EVP Chief Legal Compliance Off |
Sep 15 '26 |
Sale |
84.04 |
1,700 |
142,868 |
99,885 |
0.49%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):